MARKET

TRYPF

TRYPF

Tryp Therapeutic
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.150
+0.006
+4.46%
Closed 13:36 08/10 EDT
OPEN
0.150
PREV CLOSE
0.144
HIGH
0.150
LOW
0.150
VOLUME
770
TURNOVER
115
52 WEEK HIGH
0.768
52 WEEK LOW
0.048
MARKET CAP
14.31M
P/E (TTM)
-1.5045
1D
5D
1M
3M
1Y
5Y
TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announces that it has completed a third tranche of its pr...
CNW Group · 07/08 22:00
Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment
Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional pat...
PR Newswire · 06/29 12:00
Tryp Therapeutics appoints new COO
Tryp Therapeutics (OTCQB:TRYPF) has announced that <a href="https://seekingalpha.com/pr/18843463-tryp-ther...
Seekingalpha · 06/23 12:14
Tryp Therapeutics Appoints New Chief Operating Officer
Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that Sid Taubenfeld, a seasoned exe...
PR Newswire · 06/23 12:00
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Benzinga · 06/15 16:32
Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases.
Benzinga · 06/10 02:26
TRYP THERAPEUTICS ANNOUNCES RESULTS OF FIRST PATIENT DOSED IN ITS PHASE II CLINICAL TRIAL FOR THE TREATMENT OF BINGE EATING DISORDER
Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the initial data readout for the fi...
PR Newswire · 06/09 12:00
Tryp Therapeutics Strengthens Board of Directors with Appointment of Chris Ntoumenopoulos as Independent Director
Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Chris Ntoumenopo...
PR Newswire · 05/25 12:00
More
No Data
Learn about the latest financial forecast of TRYPF. Analyze the recent business situations of Tryp Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TRYPF stock price target is 1.174 with a high estimate of 1.174 and a low estimate of 1.174.
High1.174
Average1.174
Low1.174
Current 0.1500
EPS
Actual
Estimate
-0.03-0.02-0.02-0.01
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About TRYPF
Tryp Therapeutics Inc. is a Canada-based clinical stage pharmaceutical company. The Company is focused on developing compounds for the treatment of rare or orphan diseases and other diseases with unmet medical needs. Its lead development program, psilocybinfor-neuropsychiatry (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The indication for its PFN program is fibromyalgia. The Company is also evaluating additional indications for its PFN program, including hyperphagia in Prader Willi syndrome (PWS) and other neuropsychiatric-based chronic pain conditions and eating disorders. The Company is also engaged in developing a formulation of razoxane for the treatment of soft tissue sarcomas.

Webull offers kinds of Tryp Therapeutics Inc stock information, including OTCMQB:TRYPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRYPF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRYPF stock methods without spending real money on the virtual paper trading platform.